Our Pipeline
Cardiometabolic Pipeline
Rosuvastatin + Aspirin FDC (10/100 mg, 20/100 mg)
A combination designed for patients requiring lipid lowering and antiplatelet therapy, supporting long-term cardiovascular risk reduction in a single daily dose.
Rosuvastatin + Fenofibrate FDC (10/145 mg, 20/145 mg)
A rational combination for patients needing management of mixed dyslipidemia, targeting LDL, triglycerides, and HDL parameters in one therapy.
Orforglipron
A once-daily oral GLP-1 receptor agonist designed to improve glycemic control and support weight management in adults with type 2 diabetes.
TYRCM001
A lipid–metabolic fixed-dose combination designed to simplify therapy for patients with overlapping dyslipidemia and metabolic risk.
TYRCM002
A metabolic combination intended for high-risk patients requiring both glucose control and organ-protective therapy.
TYRCM003
A heart-failure focused combination for patients who need comprehensive cardiometabolic support in a single regimen.
Urology Pipeline
Tadalafil + Tamsulosin FDC (5 mg / 0.4 mg)
A clinically meaningful combination targeting BPH symptoms with the added benefit of improving erectile function. Designed for patients requiring dual therapy, delivered in a single daily dose to support adherence and improve symptom control.
Sildenafil + Dapoxetine FDC (100 mg / 60 mg)
A fixed-dose combination designed for patients experiencing both erectile dysfunction and premature ejaculation. This formulation aims to offer convenient, optimized, and coordinated management of both conditions.
Gastroenterology Pipeline
Vonoprazan 10 mg & 20 mg
A next-generation potassium-competitive acid blocker (P-CAB) designed for fast, potent, and sustained acid suppression, offering an alternative to traditional PPIs for GERD and acid-related conditions.
TYRGR001
A gastroprotective fixed-dose combination designed to enhance acid suppression while providing mucosal support.
TYRGR002
A combination targeting both acid-related symptoms and bloating discomfort, offering multi-symptom daily relief.
Hepatology Pipeline
Resmetirom 80 mg & 100 mg
A thyroid hormone receptor-β agonist targeting metabolic dysfunction-associated steatohepatitis (MASH/NASH).This therapy represents an important step toward addressing a significant unmet need in the region, where metabolic-driven liver disease is projected to grow rapidly over the coming decade.
Pain Management Pipeline
Diclofenac + Omeprazole FDC (75 mg / 20 mg)
A rational combination that provides anti-inflammatory and analgesic efficacy while helping protect the gastrointestinal mucosa supporting safer long-term use, particularly in patients at risk of gastric irritation.
TYRPN001
A multi-symptom analgesic combination designed to address muscular pain, tension headache , and associated discomfort in a single preparation.